Cargando…

164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities

BACKGROUND: Rapid diagnostic testing allows pathogen identification within hours of a positive blood culture. GenMark’s ePlex® Blood Culture Identification (BCID) Panels detect bacteria, fungi, and antibiotic resistance genes. This study assessed concordance of ePlex® organism identification with st...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Jenni, Clark, Justin A, Arora, Vaneet, Burgess, David, Burgess, Donna R, Mynatt, Ryan, VanHoose, Jeremy, Wallace, Katie L, Cotner, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677511/
http://dx.doi.org/10.1093/ofid/ofad500.237
_version_ 1785150147268706304
author Thomas, Jenni
Clark, Justin A
Arora, Vaneet
Burgess, David
Burgess, Donna R
Mynatt, Ryan
VanHoose, Jeremy
Wallace, Katie L
Cotner, Sarah
author_facet Thomas, Jenni
Clark, Justin A
Arora, Vaneet
Burgess, David
Burgess, Donna R
Mynatt, Ryan
VanHoose, Jeremy
Wallace, Katie L
Cotner, Sarah
author_sort Thomas, Jenni
collection PubMed
description BACKGROUND: Rapid diagnostic testing allows pathogen identification within hours of a positive blood culture. GenMark’s ePlex® Blood Culture Identification (BCID) Panels detect bacteria, fungi, and antibiotic resistance genes. This study assessed concordance of ePlex® organism identification with standard microbiologic identification methods and concordance of ePlex® genotypic resistance mechanism detection and standard susceptibility testing. Secondary outcomes included panel specific performance and characterization of antimicrobial stewardship opportunities. METHODS: This retrospective, single center study included patients with a positive blood culture from May 2020 – January 2021. Polymicrobial cultures were excluded. Identification concordance was evaluated between ePlex® and MALDI-TOF, BD Phoenix™, and biochemical tests. Resistance mechanism/phenotypic susceptibility concordance was evaluated between ePlex® and BD Phoenix(TM)/ETEST®. MecA was assessed via oxacillin resistance, vanA via vancomycin resistance, CTX-M via ceftriaxone resistance, and KPC via carbapenem resistance. Opportunities for antimicrobial stewardship were also quantified. RESULTS: The overall identification concordance rate in 1276 positive blood cultures was 98.2%, with rates of 98.5%, 98.1%, and 93.3% for Gram-positive, Gram-negative, and fungal isolates, respectively. In 381 staphylococcal isolates, concordance rates were 98.3% and 100% for the presence and absence of mecA. Both the presence and absence of vanA were 100% concordant in 63 enterococcal isolates. CTX-M and KPC were evaluated in 189 Enterobacterales. Concordance rates were 96.8% for the presence of CTX-M and 60% for the presence of KPC, demonstrating that 40% of carbapenem resistance was due to non-enzymatic mechanisms. Ceftriaxone and carbapenem susceptibility correlated with the absence of CTX-M and KPC, respectively, in 100% of cultures. A majority of ePlex results (69.5%) represented opportunities for potential antimicrobial stewardship intervention. CONCLUSION: High concordance rates between ePlex® and standard identification and susceptibility testing methods enable rapid antimicrobial optimization. Numerous opportunities for antimicrobial stewardship were identified based on ePlex® results. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677511
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106775112023-11-27 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities Thomas, Jenni Clark, Justin A Arora, Vaneet Burgess, David Burgess, Donna R Mynatt, Ryan VanHoose, Jeremy Wallace, Katie L Cotner, Sarah Open Forum Infect Dis Abstract BACKGROUND: Rapid diagnostic testing allows pathogen identification within hours of a positive blood culture. GenMark’s ePlex® Blood Culture Identification (BCID) Panels detect bacteria, fungi, and antibiotic resistance genes. This study assessed concordance of ePlex® organism identification with standard microbiologic identification methods and concordance of ePlex® genotypic resistance mechanism detection and standard susceptibility testing. Secondary outcomes included panel specific performance and characterization of antimicrobial stewardship opportunities. METHODS: This retrospective, single center study included patients with a positive blood culture from May 2020 – January 2021. Polymicrobial cultures were excluded. Identification concordance was evaluated between ePlex® and MALDI-TOF, BD Phoenix™, and biochemical tests. Resistance mechanism/phenotypic susceptibility concordance was evaluated between ePlex® and BD Phoenix(TM)/ETEST®. MecA was assessed via oxacillin resistance, vanA via vancomycin resistance, CTX-M via ceftriaxone resistance, and KPC via carbapenem resistance. Opportunities for antimicrobial stewardship were also quantified. RESULTS: The overall identification concordance rate in 1276 positive blood cultures was 98.2%, with rates of 98.5%, 98.1%, and 93.3% for Gram-positive, Gram-negative, and fungal isolates, respectively. In 381 staphylococcal isolates, concordance rates were 98.3% and 100% for the presence and absence of mecA. Both the presence and absence of vanA were 100% concordant in 63 enterococcal isolates. CTX-M and KPC were evaluated in 189 Enterobacterales. Concordance rates were 96.8% for the presence of CTX-M and 60% for the presence of KPC, demonstrating that 40% of carbapenem resistance was due to non-enzymatic mechanisms. Ceftriaxone and carbapenem susceptibility correlated with the absence of CTX-M and KPC, respectively, in 100% of cultures. A majority of ePlex results (69.5%) represented opportunities for potential antimicrobial stewardship intervention. CONCLUSION: High concordance rates between ePlex® and standard identification and susceptibility testing methods enable rapid antimicrobial optimization. Numerous opportunities for antimicrobial stewardship were identified based on ePlex® results. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677511/ http://dx.doi.org/10.1093/ofid/ofad500.237 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Thomas, Jenni
Clark, Justin A
Arora, Vaneet
Burgess, David
Burgess, Donna R
Mynatt, Ryan
VanHoose, Jeremy
Wallace, Katie L
Cotner, Sarah
164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities
title 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities
title_full 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities
title_fullStr 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities
title_full_unstemmed 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities
title_short 164. Performance of ePlex® Blood Culture Identification Panels in Clinical Isolates and Characterization of Antimicrobial Stewardship Opportunities
title_sort 164. performance of eplex® blood culture identification panels in clinical isolates and characterization of antimicrobial stewardship opportunities
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677511/
http://dx.doi.org/10.1093/ofid/ofad500.237
work_keys_str_mv AT thomasjenni 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities
AT clarkjustina 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities
AT aroravaneet 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities
AT burgessdavid 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities
AT burgessdonnar 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities
AT mynattryan 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities
AT vanhoosejeremy 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities
AT wallacekatiel 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities
AT cotnersarah 164performanceofeplexbloodcultureidentificationpanelsinclinicalisolatesandcharacterizationofantimicrobialstewardshipopportunities